Market revenue in 2022 | USD 1,700.7 million |
Market revenue in 2030 | USD 2,974.8 million |
Growth rate | 7.2% (CAGR from 2022 to 2030) |
Largest segment | Evaporative dry eye syndrome |
Fastest growing segment | Evaporative Dry Eye Syndrome |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome |
Key market players worldwide | Novartis AG ADR, AbbVie Inc, Sun Pharmaceutical Industries, Santen Pharmaceutical Co Ltd, Johnson & Johnson, Otsuka Pharmaceutical, OASIS Medical, Bausch & Lomb Corp, AFT Pharmaceuticals, Oyster Point Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dry eye syndrome treatment market will help companies and investors design strategic landscapes.
Evaporative dry eye syndrome was the largest segment with a revenue share of 82.63% in 2022. Horizon Databook has segmented the Europe dry eye syndrome treatment market based on evaporative dry eye syndrome, aqueous deficient dry eye syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of the market in the region can be attributed to an increase in research funding and the local presence of key market players in this region. The number of biopharmaceutical companies is growing in Europe, owing to increasing investments. For instance, in 2021, EIT Health, an EU-funded program initiated to improve health, chose two innovation teams to get additional support over the next 2 years: Perivision from Switzerland and INVENTION from Sweden.
The teams have received up to USD 1.70 million (EUR 1.5 million) in investment to provide novel, effective, and safe technology to Europeans with debilitating eye and visual disorders in the region. Moreover, the population in Europe is rapidly aging. According to the UN, people aged over 65 constitute 19% of the population, which accounts for about 183 million. This population is at a relatively high risk of dry eye diseases.
According to the European Ophthalmic Review, the prevalence of dry eye disease in Europe ranges from 7% to 22%. With a rapidly aging population and people becoming increasingly reliant on multiscreen devices, the burden of dry eye disease is anticipated to increase in the future. It is a chronic condition that can interfere with daily activities and lead to contact lens intolerance, may also have a negative impact on refractive surgery outcomes, and be linked to post-ocular surgery problems.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe dry eye syndrome treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe dry eye syndrome treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account